Digital-first creative agency Code and Theory has established Code and Theory Health – a new business unit dedicated to servicing brands and organizations within the healthcare industry – and added Scout Health, a 100-person agency focused on rare diseases, orphan drugs and specialty pharmaceuticals.

Global healthcare communications agency Fishawack Health acquired Skysis, a U.S.-based boutique consulting firm providing integrated market access and commercial strategy solutions.

Global healthcare communications agency Fishawack Health acquired Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the United States.

Fingerpaint acquired La Jolla, Calif.-based market access and commercialization firm 1798, and announced a new partnership with Thrive Global aimed at educating employees through personal health and wellness content and empowering them with the tools they need to improve productivity and manage stress.

W2O made three strategic acquisitions in October/November 2019 to expand the company’s capabilities. Now part of W2O are Arcus Medica; ISO.health; and Radius Digital Science.

As part of Fingerpaint’s continued commitment to bring forward the best opportunities to their clients, the full-service health and wellness marketing agency acquired 1798, a market access and commercialization firm located in La Jolla, Calif.

W2O acquired 21GRAMS – a rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human.

Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.

Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.

AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.